Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

NovaBay Pharmaceuticals (NBY) Accumulated Depreciation & Amortization (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Accumulated Depreciation & Amortization for 15 consecutive years, with $398000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $398000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $398000.0, a N/A change, with the full-year FY2024 number at $674000.0, up 1221.57% from a year prior.
  • Accumulated Depreciation & Amortization was $398000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $570000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $729000.0 in Q3 2022 to a low of $51000.0 in Q4 2023.
  • A 5-year average of $564062.5 and a median of $644500.0 in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 4264.29% in 2021, then crashed 81.28% in 2022.
  • NovaBay Pharmaceuticals' Accumulated Depreciation & Amortization stood at $641000.0 in 2021, then plummeted by 81.28% to $120000.0 in 2022, then tumbled by 57.5% to $51000.0 in 2023, then surged by 1221.57% to $674000.0 in 2024, then tumbled by 40.95% to $398000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Accumulated Depreciation & Amortization are $398000.0 (Q3 2025), $570000.0 (Q2 2025), and $569000.0 (Q1 2025).